(Q34616264)

English

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b (English)

1 reference

Europe PubMed Central

3 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Graham R Foster

1

1 reference

Europe PubMed Central

3 August 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

70

1 reference

Europe PubMed Central

3 August 2017

2

1 reference

Europe PubMed Central

3 August 2017

147-165

1 reference

Europe PubMed Central

3 August 2017

https://scigraph.springernature.com/pub.10.2165/11531990-000000000-00000

0 references

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.2165%2F11531990-000000000-00000

21 January 2018

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.2165%2F11531990-000000000-00000

21 January 2018

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.2165%2F11531990-000000000-00000

21 January 2018

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

1 reference

https://api.crossref.org/works/10.2165%2F11531990-000000000-00000

21 January 2018

Hepatitis C in the HIV-Infected Person

1 reference

https://api.crossref.org/works/10.2165%2F11531990-000000000-00000

21 January 2018

Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.

1 reference

https://api.crossref.org/works/10.2165%2F11531990-000000000-00000

21 January 2018

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compare trial: updated data

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis, management, and treatment of hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid virologic response: a new milestone in the management of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NIH Consensus Statement on Management of Hepatitis C: 2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of peginterferon in the treatment of chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of HCV infection and management on health-related quality of life

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side effects of therapy of hepatitis C and their management

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Viruses and interferons

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A step forward in therapy for hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidemiology of hepatitis C infection in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expert opinion on the treatment of patients with chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo interferon system assessed by 2'-5' oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: pegylated interferons: chemical and clinical differences

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis C virus therapy to date.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on the treatment of chronic hepatitis C in HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PEG-modified biopharmaceuticals

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The interferons. Mechanisms of action and clinical applications

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of PEGylation on biological therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response of US veterans to treatment for the hepatitis C virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon vs. standard interferon in the treatment of chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PEG-interferon alpha-2b for acute hepatitis C: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis C virus genotypes: clinical relevance and therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of peginterferon alpha-2a or -2b plus ribavirin in naïve patients with hepatitis C infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20108989

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11531990-000000000-00000

1 reference

Europe PubMed Central

3 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34616264&oldid=1953520452"